Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update.

Abstract

BACKGROUND:

Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.

CONCLUSION:

In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.

• Authors: Yi-Dong Wang, Zhen-Jie Liu, Jun Ren, Mei-Xiang Xiang
• Journal: Current vascular pharmacology (Curr Vasc Pharmacol) Vol. 16 Issue 2 Pg. 114-124 (01 26 2018) ISSN: 1875-6212 [Electronic] United Arab Emirates
• PMID: 28412911 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Cardiovascular Agents

Topics

• Animals
• Aorta, Abdominal (diagnostic imaging, drug effects, physiopathology)
• Aortic Aneurysm, Abdominal (diagnostic imaging, drug therapy, mortality, pathology)
• Cardiovascular Agents (adverse effects, therapeutic use)
• Dilatation, Pathologic
• Disease Progression
• Humans
• Risk Factors
• Treatment Outcome